Not exact matches
Dose - densified chemoimmunotherapy
followed by systemic central nervous system prophylaxis for younger high - risk diffuse large B -
cell / follicular grade 3
lymphoma patients: results of a phase II Nordic Lymphoma Grou
lymphoma patients: results of a phase II Nordic
Lymphoma Grou
Lymphoma Group study.
B
cell suppression in newborn
following treatment of pregnant diffuse large B -
cell lymphoma patient with rituximab containing regimen.
The diagnosis of 6 cases were as
follows; three diffuse large B
cell lymphomas, two mucosa - associated lymphoid tissue
lymphomas and one of other B
cell neoplasias.
Minimal Residual Disease (MRD) Status
Following Induction Chemo - Immunotherapy Predicts Progression - Free Survival In Mantle
Cell Lymphoma (MCL): CALGB 50403 (Alliance).
The targeted drug brentuximab vedotin (Adcetris ®)-- a monoclonal antibody linked to a chemotherapy drug — is approved to treat Hodgkin
lymphoma in patients whose disease has failed to respond to other treatment and, as of August 2015, to prevent relapse
following a stem
cell transplant.